Autonomous navigation for crowds of virtual humans: part I: interactive design of virtual population using navigation graphs

J. Pettré

DOI: https://doi.org/10.1145/1401132.1401196

2008-08-11

Abstract:

What problem does this paper attempt to address?

Flushing As Atypical Initial Presentation of Functional Gallbladder Neuroendocrine Carcinoma: A Case Report.

Ming Jin,Bo Zhou,Xiong-Ling Jiang,Qi-Yi Zhang,Xiang Zheng,Yuan-Cong Jiang,Sheng Yan

DOI: https://doi.org/10.3748/wjg.v26.i6.686

IF: 5.374

2020-01-01

World Journal of Gastroenterology

Abstract:BACKGROUND:Neuroendocrine neoplasms are rarely located in the gallbladder (GB), and carcinoid syndrome is exceedingly rare in patients with GB neuroendocrine neoplasms.CASE SUMMARY:We report a case of GB neuroendocrine carcinoma (GB-NEC) in a 65-year-old man, who presented with flushing for 2 mo. Pathological specimens of the flushed skin revealed that mucin was deposited between the collagen bundles in the dermis. Computed tomography and magnetic resonance imaging indicated neoplasm in the GB with liver invasion and enlarged lymph nodes in the portacaval space. High fluorodeoxyglucose uptake was detected in lymph nodes in the portacaval space, but distant metastasis was not seen by positron emission tomography. Ultrasound-guided needle biopsy of the GB neoplasm was suggestive of high-grade NEC. Because of the functional characteristics of poorly differentiated NEC, en bloc cholecystectomy, resection of hepatic segments IVb and V, pancreaticoduodenectomy, and regional lymphadenectomy were performed. A diagnosis of poorly differentiated NEC was made by pathological findings and immunohistochemical staining data. Ki-67 index was > 80%. The patient refused adjuvant therapy and passed away in the 7th month.CONCLUSION:Distinctive manifestation combined with imaging helps make correct preoperative diagnosis. Radical surgery and adjuvant chemotherapy might improve prognosis.
A Case of Long-term Survival after Curative Resection for Synchronous Solitary Adrenal Metastasis from Rectal Cancer

Linlin Chen,Da Wang,Weifang Mao,Xuefeng Huang,Chao He

DOI: https://doi.org/10.12669/pjms.301.4341

1969-01-01

Pakistan Journal of Medical Sciences

Abstract:Clinically curable adrenal metastasis is rare. We report a case of synchronous solitary adrenal metastasis from rectal cancer in a 51-year-old man who underwent curative resection. A right adrenal mass was found by ultrasonography during his routine physical examination and this was confirmed by computed tomography (CT). His serum carcinoembryonic antigen (CEA) level was found elevated, and colonoscopy revealed a rectal tumor located 10cm from anal verge. A simultaneous laparoscopic right adrenalectomy and anterior resection for rectal carcinoma was performed. Histopathological examination revealed well-differentiated rectal adenocarcinoma with adrenal metastasis. The patient is still alive and free from disease 6 years after the surgery. A review in the literature showed that synchronous solitary adrenal metastasis from colorectal carcinoma is very rare. Surgical resection and for selected patients, laparoscopic procedure may provide survival benefit and potential surgical cure for a solitary metastasis.
Long-term Survival of Gastric Mixed Neuroendocrine-Non-neuroendocrine Neoplasm: Two Case Reports.

Lun-Tao Woo,Yong-Feng Ding,Chen-Yu Mao,Jiong Qian,Xiu-Ming Zhang,Nong Xu

DOI: https://doi.org/10.12998/wjcc.v10.i22.7936

2022-01-01

World Journal of Clinical Cases

Abstract:BACKGROUND:Gastric mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN), which consists of neuroendocrine and non-neuroendocrine components, is quite rare. Until now, most data on gastric MiNEN come from clinical cases, without large-scale retrospective studies or controlled clinical trials. Consequently, no consensus regarding the origin, molecular characteristics, or appropriate treatment of MiNEN has been reached so far. We conducted chemotherapy of irinotecan plus cisplatin (IP regimen) and surgery in two patients with gastric MiNEN, which had never been used in treating this kind of tumor, leading to their long-term survival for more than 3 and 7 years, respectively.CASE SUMMARY:We present two patients (one male and one female) with gastric MiNEN, with the primary manifestation of recurrent upper abdominal pain. After they were referred to our hospital, a diagnosis of gastric MiNEN was defined with the help of CT scan, and histopathological and immunohistochemical examinations on the samples of gastrointestinal endoscopy or radical surgery. The male patient (case 1) were found to have metastases in the reginal lymph nodes and the left liver. He received four cycles of IP regimens first, then the gastrectomy and partial left liver resection, followed by additional two cycles of IP chemotherapy. The female patient (case 2) underwent a laparoscopic gastrectomy, and received six cycles of IP regimen. She was found to have metastatic lesions in the right lung 2 years after that, and underwent video-assisted thoracoscopic surgery (VATS) of the lower lobe of the right lung. The two patients have now survived for more than 3 years and 7 years, respectively, without any evidence of recurrence or metastases.CONCLUSION:IP regimen, combined with curative-intent surgery if feasible, could be considered as the priority in the choice of front-line chemotherapy for gastric MiNEN.
[Neuroendocrine Carcinoma of the Non-Ampullary Duodenum-A Case Report]

Tadashi Tsukamoto,Eijiro Edagawa,Shingo Togano,Takaaki Hori,Gen Tsujio,Tomohiro Kunimoto,Ryoji Kaizaki,Toru Inoue,Satoshi Takatsuka,Hiroko Fukushima

Abstract:A 69-year-old woman was admitted to a territory hospital because of severe right hypochondoralgia after 2 weeks of internal medicine for persistent epigastralgia. Gastroduodenal endoscopy revealed a large tumor with a fistula in the duodenal bulb that expanded to the stomach. Histopathologically, the biopsy specimen indicated a poorly differentiated adenocarcinoma and HER2 negative. Computed tomography revealed that the tumor invaded the left lobe of the liver. The patient was referred to our hospital for cancer treatment. After 1 course of chemotherapy with S-1 and CDDP, laparoscopic gastroenterostomy bypass was performed because of tumor hemorrhage and poor food intake. However, the tumor hemorrhage and poor food intake continued, and the tumor enlarged. Therefore, left hemihepatectomy and distal gastrectomy with resection of the duodenal bulb were performed 1 month after bypass surgery. Histological testing confirmed the diagnosis of duodenal large-cell neuroendocrine carcinoma invading the liver without lymph node metastasis. Adjuvant chemotherapy was not administered, and the patient has been alive without recurrence for 7 years and 3 months. Neuroendocrine carcinoma of the non-ampullary duodenum is very rare; however, a large cell type without lymph node metastasis may be a factor in the long-term prognosis.
Does Creatine Supplementation Increase the Risk of Rhabdomyolysis?

M. Juhn

DOI: https://doi.org/10.3122/15572625-13-2-150

2000-03-01

Abstract:The case report by Robinson 1 in this issue of The Journal represents the most serious published re port to date of an adverse effect in a person taking oral creatine supplements. In light of its severity, it is prudent to speculate on the likelihood that this man's creatine consumption contributed to his rhabdomyolysis. Rhabdomyolysis results from a breakdown of the muscle cell wall, which leads to cell necrosis. It is thought to be the result of a plasma membrane defect or a disturbance in the sodium-potassium pump that allows an influx of calcium into the cell, which triggers a cascade of events leading to cell necrosis. 2 Robinson speculates that intracellular water retention led to increased skeletal muscle compartment pressures, which placed the patient at risk for cellular wall breakdown. Such a hypothesis is simplistic yet worthy of consideration. It is accepted that oral creatine sup plementation results in a rapid weight gain, easily noted within 24 hours. 3 ,4 Clearly, 24 hours is not enough to induce skeletal muscle hypertrophy; the gain is the result of intracellular and extracellular fluid retention. Although no studies have evaluated creatine supplementation and its effect on muscle compartment pressures, anecdotal evidence of ath letes feeling "tight" or "cramped" abounds. Muscle cramping remains one of the most common side effects reported by those taking creatine. 5 ,6 Risk factors for rhabdomyolysis include dehy dration, alcoholism, illicit drug use, trauma, stren uous exercise, hypophosphatemia, and a hyperos molal state. 2 ,7,8 Robinson's patient had exercised the day before Robinson saw him, though his fluid and electrolyte status were not known. It has been hypothesized that creatine supplementation in creases the risk of dehydration from intravascular volume depletion. Even creatine manufacturers
Long-term Survival of an Elderly Female with Metastatic Colon Cancer after Treated with Capecitabine Monotherapy

Jin Liu,Yao Wang,Haiping Jiang,Xiongfei Yu,Nong Xu

DOI: https://doi.org/10.1097/md.0000000000014326

IF: 1.6

2019-01-01

Medicine

Abstract:RATIONALE:Colorectal cancer (CRC) is one of the most common cancers all over the world, and approximately 70% of the newly diagnosed patients are over 65 years old. Due to the aging of society, there will be more and more elderly patients of CRC in the future. Treatment of CRC in elderly patients is much more challenging thanks to multiple factors including disabling comorbidities as well as declines in organs function, especially in advanced or metastatic settings.PATIENT CONCERNS:An 82-year-old female without history of disease was admitted to the emergency room because of abdominal pain in December 2009. A computed tomography (CT) scan of the abdomen was performed immediately, which revealed bowel obstruction.DIAGNOSES:The histopathological examination of the resected specimen confirmed well-to-moderately differentiated colonic adenocarcinoma with a stage of IIIB (T3N1M0) based on the NCCN tumor-node-metastasis (TNM) classification system.INTERVENTIONS:The patient underwent emergency surgery and rejected adjuvant chemotherapy, but was diagnosed with multiple liver metastases 3 months later. Then she received capecitabine monotherapy as first-line treatment.OUTCOMES:The efficacy achieved complete response (CR) when 8 cycles were completed and the agent was continued as maintenance treatment until totally 16 cycles were completed. Up to the latest follow-up, the disease remained CR and the progression-free survival (PFS) has achieved approximately 87 months. She is still alive and has good quality of life.LESSONS:Capecitabine monotherapy may be an effective treatment in advanced or metastatic colorectal cancer (mCRC) for elderly patients.
Successful outcome achieved with adjuvant chemotherapy with irinotecan plus cisplatin in rectal neuroendocrine carcinoma: a case report

Yoshitaka Saegusa,Shintaro Akabane,Manabu Shimomura,Hiroshi Okuda,Takuya Yano,Tetsuya Mochizuki,Wako Inoue,Mizuki Yamaguchi,Shinji Yamaguchi,Kazuhiro Sentani,Masami Yamauchi,Kentaro Tokumo,Hideki Ohdan

DOI: https://doi.org/10.1186/s40792-024-02010-9

2024-09-19

Abstract:Background: Rectal neuroendocrine carcinomas (NECs) are rare and associated with poorer prognoses compared to conventional adenocarcinomas. The efficacy of adjuvant chemotherapy for resectable rectal NECs remains uncertain. Herein, we present a case of rectal NEC successfully treated with postoperative chemotherapy using irinotecan plus cisplatin. Case presentation: A 48-year-old woman with a history of endometrial cancer presented with an intramural rectal tumour detected on follow-up imaging. Colonoscopy revealed a 30 mm submucosal tumour, and laparoscopic low anterior resection was performed. Histopathological examination showed poorly differentiated atypical cells with solid growth patterns. Metastasis from the uterine cancer was ruled out due to histological differences between the primary uterine tumour and the rectal lesion, as well as the absence of hormone receptor immunohistochemical expression. Further immunohistochemical analysis revealed diffuse CD56 positivity, a high mitotic rate (> 20/10 high power fields) and a Ki-67 labelling index exceeding 70%. Based on these findings, a diagnosis of rectal NEC, T3N0M0, Stage IIB (UICC 8th edition), was established. Given the aggressive nature of the tumour evidenced by a high Ki-67 labelling index, adjuvant chemotherapy comprising six cycles of irinotecan plus cisplatin was administered to mitigate the risk of recurrence. At the 3-year follow-up, the patient was free of disease recurrence. Conclusion: This case highlights the importance of multidisciplinary surgical interventions followed by adjuvant chemotherapy in managing rectal NECs.
Primary Neuroendocrine Carcinoma of the Ileum With Markedly Elevated Carcinoembryonic Antigen (CEA) Levels: A Case Report

Aya Sugimoto,Tsutomu Nishida,Kana Hosokawa,Yoshifumi Fujii,Dai Nakamatsu,Kengo Matsumoto,Masashi Yamamoto,Koji Fukui

DOI: https://doi.org/10.7759/cureus.66676

2024-08-12

Cureus

Abstract:Neuroendocrine carcinomas (NECs) are rare and highly malignant tumors with a generally poor prognosis. Carcinoembryonic antigen (CEA) is often associated with adenocarcinoma, but its significant elevation in NEC cases is unusual. A 69-year-old man was admitted to our hospital in January 2016 due to syncope induced by anemia. The patient had a hemoglobin level of 8.0 g/dL and an ileocecal mass causing small bowel obstruction on computed tomography. His CEA level was markedly elevated at 3625.4 ng/mL. A colonoscopy revealed a neoplastic lesion in the terminal ileum, leading to an emergency ileocecal resection. Pathology confirmed a NEC, positive for synaptophysin and CEA, with a Ki-67 index of 30%. The patient was diagnosed with stage IIIb NEC (pT3N2M0). A postoperative increase in CEA to 4124.6 ng/mL and metastases in the right lung and multiple lymph nodes were detected. Initial chemotherapy with irinotecan, cisplatin (IP), and octreotide acetate proved ineffective. Subsequent octreoscans showed disease progression. Switching to everolimus as second-line therapy temporarily decreased CEA levels and tumor size, but the disease progressed with cervical lymph node involvement. The patient underwent palliative radiotherapy but succumbed to disease progression in May 2018, with a final CEA level of 36,643 ng/mL. Necropsy of the cervical lymph nodes was consistent with the original surgical findings. This case highlights the aggressive nature and challenging management of NEC with significantly elevated CEA levels.
Neurokinin A monitoring of response to interferon alpha in a patient with an advanced small bowel neuroendocrine tumour uncontrolled by somatostatin analogue therapy

Joy Es Ardill,Brian T Johnston,David R McCance,Martin Eatock

DOI: https://doi.org/10.1177/0004563216672492

Abstract:A 52-year-old lady presented with a history of occasional, severe abdominal cramps, postprandial diarrhoea and weight loss. After routine gastrointestinal investigations, she was diagnosed with irritable bowel syndrome. Over six months, she developed occasional facial flushing prompting assessment of neuroendocrine tumour markers. Urinary 5HIAA, 5HT, chromogranin A and neurokinin A were significantly elevated. Scans showed extensive hepatic metastases but did not show the location of a primary tumour. Somatostatin analogue therapy was commenced but despite increasing doses, symptoms increased and biomarkers rose dramatically. Interferon alpha was introduced concomitant with somatostatin analogue therapy. Biomarkers were monitored regularly. Within six months, symptoms abated and biomarkers reduced, continuing to fall over the next year, close to reference range. To manage side-effects of interferon alpha, dose was reduced from time to time. During these short periods, neurokinin A showed significant transient increases (75-150 ng/L) and carcinoid symptoms returned. For more than seven years, and with the co-operation of the patient, a balance was achieved between interferon alpha side-effects and disease control. Scans showed tumour load to be stable. The patient survived for 10 years post diagnosis. She chose to discontinue interferon alpha and received peptide receptor radiation therapy in her final year. Throughout, neurokinin A remained the most sensitive monitor of her disease progression.
Surface tension of water in the presence of perfluorocarbon vapors.

V. Chernyshev,M. Skliar

DOI: https://doi.org/10.1039/c3sm52289j

IF: 4.046

2014-02-26

Soft Matter

Abstract:Fluorocarbons are highly hydrophobic, biocompatible compounds with a variety of medical applications. Despite significant interest, the study of interfacial properties of fluorocarbons in aqueous systems has received limited attention. In this study, we investigate the influence of perfluoropentane and perfluorohexane vapors on the surface tension of water at room temperature. The results show a substantial decrease in the surface tension of water in the presence of perfluorocarbon vapors. In the investigated range of partial pressures up to the saturation value, a linear correlation between the surface tension and the partial pressure was found. This suggests that an adsorbed perfluorocarbon layer is formed on the surface of water. For comparison, the effect of the perfluorocarbon vapor on the surface tension of methanol was also investigated and a similar dependence was observed. Our results indicate that the stability and dynamic transitions of fluorocarbon colloids, which may be dispersed under physiological conditions as microdroplets, bubbles, or their combination, are likely affected by the composition of liquid and gas phases.
Morphogenetic aspects of the stomatognathic apparatus development in the rat.

C. Marchetti,A. Bocchieri

1985-07-01

Abstract:
Anlotinib Plus Camrelizumab Achieved Long‐term Survival in a Patient with Metastatic Esophageal Neuroendocrine Carcinoma

Lingxiao Zhou,Guanxin Xu,Tianwei Chen,Qiyuan Wang,Jing Zhao,Ting Zhang,Rong Duan,Yang Xia

DOI: https://doi.org/10.1002/cnr2.1855

2023-01-01

Cancer Reports

Abstract:Abstract Background Esophageal neuroendocrine carcinoma (NEC) is a rare cancer with an extremely poor prognosis. The average overall survival of patients with metastatic disease is only 1 year. The efficacy of anti‐angiogenic agents combined with immune checkpoint inhibitors remains unknown. Case Presentation A 64‐year‐old man, initially diagnosed with esophageal NEC, underwent neoadjuvant chemotherapy and esophagectomy. Although the patient remained disease‐free for 11 months, eventually the tumor progressed and did not respond to three lines of combined therapy (etoposide plus carboplatin with local radiotherapy, albumin‐bound paclitaxel plus durvalumab, and irinotecan plus nedaplatin). The patient then received anlotinib plus camrelizumab, and a dramatic regression was observed (confirmed by positron emission tomography‐computed tomography). The patient has been disease‐free for over 29 months and has survived for over 4 years since diagnosis. Conclusion Combined therapy with anti‐angiogenic agents and immune checkpoint inhibitors may be a promising strategy for esophageal NEC, although more evidence is warranted to validate its efficacy.
Developing Laboratory Systems and Infrastructure for HIV Scale-Up: A Tool for Health Systems Strengthening in Resource-Limited Settings

J. Justman,S. Koblavi-Dème,A. Tanuri,A. Goldberg,L. Gonzalez,Charon Gwynn

DOI: https://doi.org/10.1097/QAI.0b013e3181bbc9f5

2009-11-01

Journal of Acquired Immune Deficiency Syndromes

Abstract:The rapid scale-up of HIV care and treatment in resource-limited settings has overwhelmed many public health laboratory services already burdened with human resource shortages, an aging and inadequate infrastructure, and a lack of quality systems. There is, however, a growing appreciation of the opportunity to use HIV-related laboratory strengthening as means to strengthen health systems in general. We briefly describe ongoing efforts to integrate HIV laboratory support into HIV care and treatment systems, thereby strengthening laboratory systems in support of both HIV scale-up and overall health systems strengthening.
The skin as a window to the gut: A case of carcinoid syndrome

Catarina Alves Costa,Tânia Lopes,Ana Patrícia Rodrigues,Nuno Jorge Lamas,Célia Cruz

DOI: https://doi.org/10.1002/ccr3.8641

2024-03-07

Abstract:Neuroendocrine tumors (NETs) are a group of uncommon neoplasms derived from enterochromaffin or Kulchitsky cells (that secrete serotonin or other molecules into the bloodstream), which can manifest with symptoms of hormonal overproduction, namely carcinoid syndrome (CS). This can be the presenting feature in patients with advanced disease. We report the case of a 66-year-old woman presenting with chronic diarrhea, facial venous telangiectasia and elevated urinary 5-hydrocyindoleacetic acid levels. A 68-Ga DOTATOC PET/CT scan revealed an ileal mass and lesions consistent with liver, ovary and bone metastasis. A liver biopsy confirmed the diagnosis of well-differentiated NET G1. Therapy with somatostatin analogs achieved symptom control, but the liver disease progressed and the patient passed away after 2 years of follow-up. The challenge of diagnosing CS resides in its heterogeneous manifestations, which may range from mild to life-threatening conditions. In this case, the cutaneous findings of venous telangiectasia strongly pointed to the correct diagnosis. Treatment can also be difficult due to refractory symptoms and inevitable progression of disease, highlighting the importance of early detection and thorough disease staging.
Complete Response to Immunotherapy Combined with Chemotherapy in a Patient with Gynecological Mixed Cancer Mainly Composed of Small Cell Neuroendocrine Carcinoma with High Tumor Mutational Burden: A Case Report

Xingyun Su,Xinhui Zhou,Cheng Xiao,Wei Peng,Qiangfeng Wang,Yulong Zheng

DOI: https://doi.org/10.3389/fonc.2022.750970

IF: 4.7

2022-01-01

Frontiers in Oncology

Abstract:Small cell neuroendocrine carcinoma (SCNEC) is rare in the gynecologic tract, which has high invasive and metastatic ability. Due to the aggressive behavior and lack of treatment, patients have an extremely poor prognosis. Here we report a 66-year-old female diagnosed with SCNEC in the gynecologic tract, mixed with endometrioid adenocarcinoma, squamous cell, and adenosquamous carcinoma. A tumor mutational burden of 13.14 Muts/Mb was detected by next-generation sequencing. The patient underwent a palliative operation of total hysterectomy with bilateral adnexectomy but suffered from disease progression in a short time after the operation. Chemotherapy (paclitaxel + carboplatin) combined with immunotherapy (toripalimab) was conducted every 3 weeks, achieving a partial response after 2 cycles of treatment. After 5 cycles of combined treatment, the patient consolidated with monotherapy of toripalimab for about half a year and achieved a complete response. Until December 2021, the patient has achieved 27 months of progression-free survival and maintains a continued complete response. This case is presented due to the rare combination of pathological types and durable response to treatment especially immunotherapy, suggesting the potential value of immunotherapy in SCNEC of the gynecologic tract.
Case Report: The molecular fingerprint and the clinical implication of an exceptional response to neoadjuvant therapy in a metastatic cardia adenocarcinoma

Laura Lorenzon,Andrea Campisi,Alessandra Di Paolo,Felice Giuliante,Fiamma Buttitta,Domenico D’Ugo

DOI: https://doi.org/10.3389/fsurg.2024.1297083

IF: 1.8

2024-04-16

Frontiers in Surgery

Abstract:Background Globally, gastric cancer holds the fifth position in terms of prevalence among malignant tumors and is the fourth leading cause of cancer-related mortality. Particular attention should be paid to cardia adenocarcinoma (CA) due to its increasing incidence and poor prognosis. Diagnosis of CA frequently occurs in advanced stages because of its late symptoms. In such cases, neoadjuvant chemotherapy is the primary treatment option. The response to chemotherapy depends on multiple variables including the tumor's molecular profile, the patient's performance status, and the feasibility of using targeted therapy. Patients exhibiting an exceptional response, defined as a complete response to medical therapy lasting more than 1 year, or a partial response or stable disease lasting more than 2 years, are rarely described. This case report presents one of the longest-lasting exceptional responses to chemotherapy in metastatic cardia adenocarcinoma and discusses its clinical implications. Case presentation A 49-year-old male patient presented with cardia adenocarcinoma (human epidermal growth factor receptor 2 negative, mismatch repair proficient) and liver metastases. Molecular profiling identified a pathogenic mutation in the TP53 gene (R123W; Arg123Trp) as the sole alteration found. Five months after initiating the neoadjuvant chemotherapy with fluorouracil–leucovorin–oxaliplatin–docetaxel, the patient achieved a complete clinical response. The molecular profile was compared with others previously documented in an international data portal, revealing a similar pattern. At 4 years and 3 months from diagnosis, the exceptional response was still confirmed. The patient underwent a cumulative number of 33 cycles of chemotherapy, leading to chemotherapy-induced liver damage. Conclusions Exceptional responses to neoadjuvant chemotherapy in cardia adenocarcinomas are rarely reported. The documentation of exceptional responses to cancer therapies should be included in large data repositories to explore the molecular fingerprint of these tumors. In such cases, the clinical implications of long-term chemotherapy should always be taken into account.

surgery
Long‐term survival after comprehensive treatment in a patient with advanced neuroendocrine neoplasm of the pancreas: A case report

Lei Zhao,Xin Cheng,Hongbin Zhao,Haifei Zhao,Wenyu Di,Zhihong Mei

DOI: https://doi.org/10.3892/ol.2024.14795

2024-11-10

Oncology Letters

Abstract:Neuroendocrine neoplasms of the pancreas (pNENs) are rare. In February 2021, a 54‐year‐old woman was diagnosed with pNEN and multiple metastases within the liver. The patient, diagnosed with grade G2 neuroendocrine neoplasm (T4N0M1), underwent an ultrasonography‐guided liver biopsy and radiofrequency ablation. After receiving Sandostatin LAR in April 2021, side effects led to its discontinuation after seven cycles. Following two sessions of radiofrequency ablation, the patient's condition was stable. However, disease progression was noted in September 2023, resulting in hemodialysis and closed peritoneal drainage. Surufatinib was administered, stabilizing the tumor by November 2023. The patient underwent transarterial chemoembolization due to a large tumor burden, with subsequent MRCP showing stability from diagnosis in February 2021 to June 2024. The present case report highlights the role of tailored treatment strategies considering patient comorbidities and tumor biology, and the significance of secondary puncture biopsy, which, despite not being pursued by the patient in the present study due to the associated risks, may provide survival benefits for patients with advanced or metastatic pNEN.

oncology
[A Case of Long-Term Survival after Surgeries for Gastric Cancer and Metachronous Ovarian Metastasis]

Tatsuya Yoshida,Naoki Wajima,Harue Akasaka,Shingo Sakuraba,Takahiro Muroya,Norihito Kubo,Kensuke Okano,Chiaki Uchida,Kenichi Hakamada

Abstract:The patient was a 57-year-old woman. In October 2011, she underwent distal gastrectomy, D2 lymphadenectomy, and Roux-en-Y reconstruction for gastric cancer (pT4a, pN3b, Stage ⅢC [JCGC 14th Edition]). She then received S-1 plus CDDP combination therapy and S-1 monotherapy as postoperative adjuvant chemotherapies for 1 year, and was followed up as an outpatient. In April 2013, a significant increase in the CA19-9 level was noted, and CT indicated a right ovarian tumor. Ovarian metastasis from the gastric cancer was diagnosed, and the response to 3 courses of weekly PTX was stable disease. No findings indicated metastasis to other organs. In July 2013, a salpingo-oophorectomy was performed, after which her CA19-9 level returned to the normal range. Follow-up was adopted as the postoperative strategy in part due to the desires of the patient. Presently, 3 years and 6 months after the initial surgery and 1 year and 9 months after the last surgery, no recurrence has been detected. Generally, ovarian metastasis from gastric cancer is considered to be associated with a poor prognosis. However, our patient showed long-term survival after surgeries for gastric cancer and asynchronous ovarian metastasis. Here, we report the details of our case and review the relevant literature.
[Long-Term Survival of a Case with Peritoneal Dissemination from Appendiceal Goblet Cell Carcinoid Treated with Systemic Chemotherapy]

Yutaka Yagi,Takashi Kobayashi,Takaoki Watanabe,Michiru Arabiki

Abstract:A 64-year-old man complained of lower abdominal pain and vomiting. The CT scan showed adhesional ileus; therefore, small bowel resection procedure was performed. Histological findings showed signet-ring cell carcinoma and poorly differentiated adenocarcinoma. We performed ileocecal resection as an additional surgery. The operative findings revealed peritoneal nodules. The histological findings suggested goblet cell carcinoid with peritoneal dissemination. mFOLFOX+bevacizumab was administered, and no progression was observed for 30 months after the surgery. Appendiceal goblet cell carcinoid is rare and its prognosis is poor. Here, we report a case of appendiceal GCC that achieved a relatively long-term survival despite peritoneal dissemination.
Late-stage Esophageal Neuroendocrine Carcinoma in a Patient Treated with Tislelizumab Combined with Anlotinib: a Case Report.

Yanqi Zhang,Xiaoyu Liu,Honglu Liang,Weihua Liu,Haiyan Wang,Tao Li

DOI: https://doi.org/10.1177/03000605231187942

2023-01-01

Journal of International Medical Research

Abstract:Esophageal neuroendocrine carcinoma (ENEC) is an extremely rare tumor with highly malignant potential, rapid growth, and a poor prognosis. Advanced extrapulmonary neuroendocrine carcinoma should be treated with chemotherapeutic regimens suitable for small cell lung cancer. However, ENEC has no clear second-line treatment options. The clinical application of immunotherapy and targeted therapy in small cell lung cancer has produced good therapeutic effects. We describe the case of an elderly woman with multiple metastatic advanced ENEC treated with tislelizumab combined with anlotinib as second-line therapy, achieving complete remission in a short period and long-term survival. In total, 21 cycles of tislelizumab combined with anlotinib were given to this patient. After two cycles, the patient's neuron-specific enolase level decreased from 181.8 to 22.9 µg/L and remained at normal levels throughout treatment. Progression-free survival and overall survival were 16 and 21 months, respectively, in this patient. No obvious side effects were observed. Thus, tislelizumab and anlotinib could represent a novel therapeutic option for advanced ENEC.

Autonomous navigation for crowds of virtual humans: part I: interactive design of virtual population using navigation graphs

Flushing As Atypical Initial Presentation of Functional Gallbladder Neuroendocrine Carcinoma: A Case Report.

A Case of Long-term Survival after Curative Resection for Synchronous Solitary Adrenal Metastasis from Rectal Cancer

Long-term Survival of Gastric Mixed Neuroendocrine-Non-neuroendocrine Neoplasm: Two Case Reports.

[Neuroendocrine Carcinoma of the Non-Ampullary Duodenum-A Case Report]

Does Creatine Supplementation Increase the Risk of Rhabdomyolysis?

Long-term Survival of an Elderly Female with Metastatic Colon Cancer after Treated with Capecitabine Monotherapy

Successful outcome achieved with adjuvant chemotherapy with irinotecan plus cisplatin in rectal neuroendocrine carcinoma: a case report

Primary Neuroendocrine Carcinoma of the Ileum With Markedly Elevated Carcinoembryonic Antigen (CEA) Levels: A Case Report

Neurokinin A monitoring of response to interferon alpha in a patient with an advanced small bowel neuroendocrine tumour uncontrolled by somatostatin analogue therapy

Surface tension of water in the presence of perfluorocarbon vapors.

Morphogenetic aspects of the stomatognathic apparatus development in the rat.

Anlotinib Plus Camrelizumab Achieved Long‐term Survival in a Patient with Metastatic Esophageal Neuroendocrine Carcinoma

Developing Laboratory Systems and Infrastructure for HIV Scale-Up: A Tool for Health Systems Strengthening in Resource-Limited Settings

The skin as a window to the gut: A case of carcinoid syndrome

Complete Response to Immunotherapy Combined with Chemotherapy in a Patient with Gynecological Mixed Cancer Mainly Composed of Small Cell Neuroendocrine Carcinoma with High Tumor Mutational Burden: A Case Report

Case Report: The molecular fingerprint and the clinical implication of an exceptional response to neoadjuvant therapy in a metastatic cardia adenocarcinoma

Long‐term survival after comprehensive treatment in a patient with advanced neuroendocrine neoplasm of the pancreas: A case report

[A Case of Long-Term Survival after Surgeries for Gastric Cancer and Metachronous Ovarian Metastasis]

[Long-Term Survival of a Case with Peritoneal Dissemination from Appendiceal Goblet Cell Carcinoid Treated with Systemic Chemotherapy]

Late-stage Esophageal Neuroendocrine Carcinoma in a Patient Treated with Tislelizumab Combined with Anlotinib: a Case Report.